Novel drug - dinutuximab for high-risk neuroblastoma
Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!